NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Al B. Benson, Alan P. Venook(UCSF Helen Diller Family Comprehensive Cancer Center), Mahmoud M. Al-Hawary(University of Michigan–Ann Arbor), Lynette Cederquist(Moores Cancer Center), Yi‐Jen Chen(City of Hope), Kristen K. Ciombor(Breast Cancer Research Foundation), Stacey A. Cohen(Seattle Cancer Care Alliance), Harry S. Cooper(Fox Chase Cancer Center), Dustin A. Deming(University of Wisconsin Carbone Cancer Center), Paul F. Engstrom(Fox Chase Cancer Center), Ignacio Garrido‐Laguna(Huntsman Cancer Institute), Jean L. Grem(Taiho Oncology (United States)), Axel Grothey(WinnMed), Howard S. Höchster(Yale Cancer Center), Sarah E. Hoffe(Moffitt Cancer Center), Steven R. Hunt(Jewish Hospital), Ahmed Kamel(University of Alabama at Birmingham), Natalie Kirilcuk(Cancer Institute (WIA)), Smitha Krishnamurthi(University Hospitals Seidman Cancer Center), Wells A. Messersmith(University of Colorado Denver), Jeffrey A. Meyerhardt(Dana-Farber Brigham Cancer Center), Eric D. Miller(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Mary F. Mulcahy, James D. Murphy(Moores Cancer Center), Steven Nurkin(Taiho Oncology (United States)), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Sunil Sharma(Huntsman Cancer Institute), David Shibata(University of Tennessee Health Science Center), John M. Skibber(The University of Texas MD Anderson Cancer Center), Constantinos T. Sofocleous(Memorial Sloan Kettering Cancer Center), Elena M. Stoffel(University of Michigan–Ann Arbor), Eden Stotsky‐Himelfarb(Sidney Kimmel Comprehensive Cancer Center), Christopher G. Willett(Duke Cancer Institute), Evan Wuthrick(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kristina M. Gregory(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 1,028Open Access
Abstract
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of recurrent and metastatic disease, and survivorship. These NCCN Guidelines Insights summarize the NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation–positive metastatic colorectal cancer with regimens containing vemurafenib.
Related Papers
No related papers found
Powered by citation graph analysis